RSS Neurocrine Announces Commercial Launch Of Crenessity In US

Currently reading:
 RSS Neurocrine Announces Commercial Launch Of Crenessity In US

Status
Not open for further replies.

Crax Bot

Staff member
Administrator
Amateur
LV
0
Joined
Nov 5, 2021
Threads
6,205
Likes
1,915
Credits
32,754©
Cash
0$
Neurocrine Biosciences, Inc. (NBIX) has announced the U.S. commercial launch of Crenessity, a treatment for adult and pediatric patients with classic congenital adrenal hyperplasia (CAH), a rare genetic disorder. This launch comes after the U.S. Food and Drug Administration approved Crenessity as an adjunct therapy to glucocorticoid replacement, aimed at controlling androgens in CAH patients.

The biopharmaceutical firm stated that Crenessity will be exclusively distributed through PANTHERx Rare, a specialty pharmacy. As of pre-market trading, Neurocrine's shares are at $134.01, representing a 0.70 percent decrease on the Nasdaq.

The material has been provided by InstaForex Company - www.instaforex.com
 
Status
Not open for further replies.
Tips
Top Bottom